AmideBio

AmideBio is a preclinical-stage biotechnology company dedicated to a range of therapeutic targets and diagnostics in the field of diabetes-related metabolic diseases. The company's leading program focuses on novel glucose-responsive insulin (GRIs), which will eliminate the need for basal and mealtime insulin, requiring only a once-weekly dose.